SARS-CoV-2 Spike-Binding Polypeptides via CDR Segmentation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a critical unmet need for effective therapies to treat and prevent coronavirus infections, particularly for SARS-CoV and SARS-CoV-2, given the emergence of COVID-19.

Innovation Solution

Development of polypeptides with specific antigen-binding domains that selectively bind to the spike glycoprotein of SARS-CoV and SARS-CoV-2, including defined CDR1, CDR2, and CDR3 sequences, which can be used to create pharmaceutical compositions for therapeutic applications.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If polypeptides with specific antigen-binding domains are developed to selectively bind to spike glycoprotein, then binding specificity and therapeutic effectiveness are improved, but device complexity and manufacturing difficulty increase

Engineering Contradiction:

Improvebinding specificityVSAvoidpolypeptide structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The antigen-binding domain is segmented into three specific CDR regions (CDR1, CDR2, CDR3) with defined sequences. Each CDR region is independently characterized with specific amino acid positions and allowed variations, allowing modular design and analysis of binding specificity while managing structural complexity through systematic segmentation of the polypeptide chain.

Inventive Principle:

Principle #1Segmentation

2Reliability

If polypeptides with specific antigen-binding domains are developed to selectively bind to spike glycoprotein, then therapeutic effectiveness is improved, but ease of manufacture deteriorates

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidpolypeptide production ease

Core Design Contradiction:

ReliabilityVSEase of manufacture

Solution Approach 1:

The patent defines specific parameter ranges for each CDR region, including allowed amino acid substitutions at specific positions (e.g., CDR1 positions 1-10 with specific allowed residues). This parameter-based definition allows for controlled variation and optimization of therapeutic effectiveness while providing clear guidelines for manufacturing consistency and quality control.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20240059759A1SARS-cov(-2) spike glycoprotein-binding domains and polypeptides comprising the same and use of the same

Publication Date: 2024.02.22 BIGHAT BIOSCIENCES INC

AI summary

Provided herein are antigen-binding domains that specifically bind to a SARS-CoV(-2) spike glycoprotein, polypeptides comprising the same, and uses of the same.